TAS-1553

N/A

Report date: 2024/08/26 10:53:00
NME

Base Information

Drug NameTAS-1553
Drug Alias NameTAS-1553
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRibonucleotide reductase inhibitors
TargetsRibonucleotide reductase
Therapy Area/IndicationsMyeloproliferative DisordersMyelodysplastic-Myeloproliferative DiseasesLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstex Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstex Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsMyeloproliferative DisordersMyelodysplastic-Myeloproliferative DiseasesLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A